{"id":"NCT00168818","sponsor":"Boehringer Ingelheim","briefTitle":"Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery","officialTitle":"A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With Half Dose (75 or 110 mg) on the Day of Surgery] Compared to Subcutaneous Enoxaparin 40 mg Once Daily for 28-35 Days, in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip Replacement Surgery. RE-NOVATE (Extended Thromboembolism Prevention After Hip Surgery)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-11","primaryCompletion":"2006-07","completion":null,"firstPosted":"2005-09-15","resultsPosted":"2010-12-20","lastUpdate":"2014-05-19"},"enrollment":3494,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Thromboembolism","Arthroplasty, Replacement, Hip"],"interventions":[{"type":"DRUG","name":"dabigatran etexilate","otherNames":[]},{"type":"DRUG","name":"dabigatran etexilate","otherNames":[]},{"type":"DRUG","name":"enoxaparin","otherNames":[]}],"arms":[{"label":"dabigatran etexilate 75 mg","type":"EXPERIMENTAL"},{"label":"dabigatran etexilate 110 mg","type":"EXPERIMENTAL"},{"label":"enoxaparin","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to determine the comparative efficacy and safety of two oral regimens of dabigatran etexilate, compared to a standard subcutaneous regimen of enoxaparin, in prevention of venous thromboembolism in patients with primary elective total hip replacement surgery.","primaryOutcome":{"measure":"Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period","timeFrame":"First administration until 31-38 days","effectByArm":[{"arm":"Dabigatran 220mg","deltaMin":53,"sd":null},{"arm":"Dabigatran 150mg","deltaMin":75,"sd":null},{"arm":"Enoxaparin","deltaMin":60,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.5648"},{"comp":"OG001 vs OG002","p":"0.1339"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":116,"countries":["Australia","Austria","Belgium","Czechia","Denmark","Finland","France","Germany","Hungary","Italy","Netherlands","Norway","Poland","South Africa","Spain","Sweden"]},"refs":{"pmids":["26578849","22995531","22709460","17869635"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":89,"n":1146},"commonTop":["Nausea","Vomiting","Constipation","Pyrexia","Insomnia"]}}